Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.
Investigators plan to identify patients with small papillary thyroid carcinoma and subject such patients to radiofrequency ablation (RFA) therapy. Following RFA procedure patients will be monitored to study the changes in primary tumor volume, development of lymph node involvement, development of distant metastasis and changes in serum thyroid hormone levels. Investigators will also assess the stability of these changes (need for repeat therapy) and the safety of the RFA procedure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
5
Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.
Mayo Clinic
Rochester, Minnesota, United States
Changes in Thyroid Nodule Size
Thyroid tumor volume shrinkage will be assessed by ultrasound and compared with pre-procedure volume (measure in mL)
Time frame: 24 months
Pain Related to RFA Procedure
Assessed by number of participants that reported any pain related to RFA procedure
Time frame: Up to 24 months
Development of Lymph Node Involvement
Assessed by the number of participants with cervical adenopathy (enlargement of lymph nodes in the neck area). Participants will be evaluated during follow-up visits.
Time frame: 18 months
Development of Distant Metastasis
Assessed by the number of participants with distant metastasis if regional neck metastasis is detected on follow up.
Time frame: 18 months
Safety of the RFA Procedure
Assessed by the number of participants who experienced infection, hematoma, bruising, or other complications at the RFA site.
Time frame: Up to 24 months
Change in Thyroid Status
Participants were tracked for thyroid status following radiofrequency ablation
Time frame: Up to 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.